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Background Finding the right drug-dosage for neonates is still
a medical challenge. Up to now, neonatal doses are extrapo-
lated from adult and children doses. However, there are dif-
ferences between neonatal and adult kidney physiology that
should be put into consideration, especially when it comes to
active drug metabolism. Studying renal drug clearances in neo-
nates is limited by the lack of reliable human cell models.
Our aim was to illustrate the feasibility to develop an in vitro
model for neonatal proximal tubule epithelial cells (nPTECs)
for studying renal drug clearances at this age.
Method nPTECs were isolated from urine samples of ne-
onates of different gestational age (GA) and conditionally
immortalised using a temperature sensitive SV40T anti-gen and
human telomerase hTERT. The cell clones were characterised
on gene expression level for PTECs markers such as P-glyco-
protein (P-gp), aquaporin1 (AQP1), and organic cation trans-
port protein 2 (OCT2). In addition, protein expression and
functional assessment were per-formed for P-gp and OCT2.
Results We established 101 clonal cell lines of cinPTECs
derived from neonatal urine. Gene expression analy-sis con-
firmed the expression of the PTECs (P-gp, AQP1, and
OCT2), similar to the expression in the adult control ciP-
TECs. P-gp was expressed in cinPTECs from the differ-ent
gestational ages and exhibited similar functionality as the adult
derived ciPTECs. In contrast, OCT2 functionality was signifi-
cantly lower in the cinPTECs cell lines com-pared to the adult
ciPTECs.
Conclusion We demonstrate the feasibility of culturing cinP-
TECs expressing mature ciPTECs markers with high efficiency
out of the urine samples of neonates. The cell model pre-
sented here can serve as a valuable tool to study proximal
tubule physiology and pharmacology in new-borns. In addi-
tion, we demonstrate the physiolog-ical differences between
the neonatal and adult kidney, which puts emphasise on the
importance of studying drug pharmacokinetics in neonatal
models instead of ex-trapolating from adult models.
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Background Megalin-mediated endocytosis is the prin-cipal
pathway for the accumulation of aminoglycosides in proximal
tubule epithelial cells,1 resulting in kidney toxicity. Activation
of this pathway depends on intermediates derived from meval-
onate, the product of 3-hydroxy-3-meth-ylglutaryl-coenzyme A
(HMG-CoA) reduction, catalysed by HMG-CoA reductase.2
We hypothesised that inhibition of HMG-CoA reductase by
statins would reduce uptake of aminoglycosides in the proxi-
mal tubule, leading to a re-duction in toxicity. This has previ-
ously been demonstrated in vitro.3 We tested this in two in
vivo models.
Methods Sprague Dawley rats, (n=4/group) received in-traperi-
toneal (IP) dosing with saline (control), gentamicin (200 mg/
kg/day), rosuvastatin (40 mg/kg/day), or gentami-cin and rosu-
vastatin for 9 days. Nephrotoxicity was measured using uri-
nary N-Acetyl-b-d-glucosaminidase (NAG) and kidney injury
molecule-1 (kim-1) on urine samples collected within 24 hours
after the final dose. Male Hartley guinea pigs (n=6/group)
received IP dosing with saline (control), gentamicin (100 mg/
kg/day), statin, or combined gentami-cin and statin (simvastatin
or rosuvastatin, 0.4 to 40 mg/kg/day) for 9 days. Nephrotoxic-
ity was measured using serum creatinine and blood urea nitro-
gen (BUN) on urine samples collected within 24 hours after
the final dose.
Results In rats co-administered rosuvastatin and gentami-cin,
urinary concentrations of NAG and kim-1 were signifi-cantly
lower than for gentamicin alone (p<0.01). In guinea pigs,
rosuvastatin reduced gentamicin-induced nephro-toxicity in a
dose-dependent manner: doses of 0.4, 4 and 40mg/kg/day led
to 46% (p<0.01), 81% (p<0.0001), and 83% (p<0.0001)
reductions, respectively, in serum creati-nine compared to ani-
mals receiving gentamicin only. Simi-lar results were seen with
BUN. The minimum effective dose to prevent toxicity was
0.97mg/kg/day. Using a dose scaling algorithm this equates to
a dose of 10mg/day in children. Simvastatin did not protect
the kidney from gentamicin-in-duced nephrotoxicity. The
results from the in vitro and in vivo animal studies led to the
design of a phase IIa multi-centre, randomised, controlled clin-
ical trial (RCT) in children with cystic fibrosis receiving clini-
cally indicated treatment with aminoglycosides, where co-
treatment with rosuvasta-tin (10mg) will be compared with
current standard of care.
Conclusion Rosuvastatin inhibits gentamicin-induced nephro-
toxicity in both rat and guinea pig models; in the latter, at
therapeutic doses used in humans. This led to an RCT in chil-
dren which has just completed recruitment. This bench-to-bed-
side translational research showcases the exciting area of drug
repurposing with potential for signifi-cant patient benefit.
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